Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 454

1.

Simulation-based power and sample size calculation for designing interrupted time series analyses of count outcomes in evaluation of health policy interventions.

Liu W, Ye S, Barton BA, Fischer MA, Lawrence C, Rahn EJ, Danila MI, Saag KG, Harris PA, Lemon SC, Allison JJ, Zhang B.

Contemp Clin Trials Commun. 2019 Oct 16;17:100474. doi: 10.1016/j.conctc.2019.100474. eCollection 2020 Mar.

2.

Comorbidities in gout and hyperuricemia: causality or epiphenomena?

Sumpter NA, Saag KG, Reynolds RJ, Merriman TR.

Curr Opin Rheumatol. 2019 Dec 23. doi: 10.1097/BOR.0000000000000691. [Epub ahead of print]

PMID:
31876630
3.

Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study.

Chaudhary NS, Bridges SL Jr, Saag KG, Rahn EJ, Curtis JR, Gaffo A, Limdi NA, Levitan EB, Singh JA, Colantonio LD, Howard G, Cushman M, Flaherty ML, Judd S, Irvin MR, Reynolds RJ.

Hypertension. 2020 Jan;75(1):246-256. doi: 10.1161/HYPERTENSIONAHA.119.13580. Epub 2019 Dec 2.

PMID:
31786980
4.

Pragmatic Clinical Trials in Osteoporosis.

Adami G, Saag KG, Danila MI.

Curr Osteoporos Rep. 2019 Dec;17(6):521-526. doi: 10.1007/s11914-019-00551-9. Review.

PMID:
31773402
5.

Association of Early Postoperative Pain Trajectories With Longer-term Pain Outcome After Primary Total Knee Arthroplasty.

Singh JA, Lemay CA, Nobel L, Yang W, Weissman N, Saag KG, Allison J, Franklin PD.

JAMA Netw Open. 2019 Nov 1;2(11):e1915105. doi: 10.1001/jamanetworkopen.2019.15105.

6.

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.

Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J-.

Osteoporos Int. 2020 Jan;31(1):1-12. doi: 10.1007/s00198-019-05176-3. Epub 2019 Nov 13.

PMID:
31720707
7.

Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.

Adami G, Jaleel A, Curtis JR, Delzell E, Chen R, Yun H, Daigle S, Arora T, Danila MI, Wright NC, Cadarette SM, Mudano A, Foster J, Saag KG.

J Bone Miner Res. 2019 Nov 12. doi: 10.1002/jbmr.3915. [Epub ahead of print]

PMID:
31714637
8.

Balancing benefits and risks in the era of biologics.

Adami G, Saag KG, Chapurlat RD, Guañabens N, Haugeberg G, Lems WF, Matijevic R, Peel N, Poddubnyy D, Geusens P.

Ther Adv Musculoskelet Dis. 2019 Oct 24;11:1759720X19883973. doi: 10.1177/1759720X19883973. eCollection 2019. Review.

9.
10.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators.

Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31.

PMID:
31676222
11.

Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice.

Adami G, Rahn EJ, Saag KG.

Ther Adv Musculoskelet Dis. 2019 Sep 20;11:1759720X19876468. doi: 10.1177/1759720X19876468. eCollection 2019. Review.

12.

Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.

Conley RB, Adib G, Adler RA, Åkesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman-Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Kužma M, Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N, Napoli N, Olenginski TP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel DP.

J Bone Miner Res. 2020 Jan;35(1):36-52. doi: 10.1002/jbmr.3877. Epub 2019 Dec 1.

PMID:
31538675
13.

Characteristics of older adults using patient web portals to view their DXA results.

Edmonds S, Lou Y, Robinson B, Cram P, Roblin DW, Wright NC, Saag K, Wolinsky FD.

BMC Med Inform Decis Mak. 2019 Sep 18;19(1):187. doi: 10.1186/s12911-019-0904-y.

14.

Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study.

Wallace BI, Lin P, Kamdar N, Noureldin M, Hayward R, Fox DA, Curtis JR, Saag KG, Waljee AK.

Semin Arthritis Rheum. 2019 Sep 7. pii: S0049-0172(19)30106-4. doi: 10.1016/j.semarthrit.2019.09.002. [Epub ahead of print]

PMID:
31522762
15.

Design, analysis, power, and sample size calculation for three-phase interrupted time series analysis in evaluation of health policy interventions.

Zhang B, Liu W, Lemon SC, Barton BA, Fischer MA, Lawrence C, Rahn EJ, Danila MI, Saag KG, Harris PA, Allison JJ.

J Eval Clin Pract. 2019 Aug 19. doi: 10.1111/jep.13266. [Epub ahead of print]

PMID:
31429175
16.

Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in the National Veterans Administration Gout Cohort.

Singh JA, Yang S, Saag KG.

J Rheumatol. 2019 Aug 15. pii: jrheum.190522. doi: 10.3899/jrheum.190522. [Epub ahead of print]

PMID:
31416925
17.

Come from away: Best practices in mini-sabbaticals for the development of young investigators: a White Paper by the SEQUIN (mini-Sabbatical Evaluation and QUality ImprovemeNt) Group.

Pillinger MH, Lemon SC, Zand MS, Foster PJ Jr, Merchant JS, Kimberly R, Allison J, Cronstein BN, Galeano C, Holden-Wiltse J, Trayhan M, White RJ, Davin A, Saag KG.

J Clin Transl Sci. 2019 Feb;3(1):37-44. doi: 10.1017/cts.2019.369. Review.

18.

Burosumab in tumor-induced osteomalacia: A case report.

Day AL, Gutiérrez OM, Guthrie BL, Saag KG.

Joint Bone Spine. 2020 Jan;87(1):81-83. doi: 10.1016/j.jbspin.2019.07.012. Epub 2019 Aug 3.

PMID:
31382017
19.

Vascular Consequences of Hyperuricemia and Hypouricemia.

Albert D, Scudder PN, Bagley P, Saag KG.

Rheum Dis Clin North Am. 2019 Aug;45(3):453-464. doi: 10.1016/j.rdc.2019.04.005. Epub 2019 Jun 5. Review.

PMID:
31277755
20.

Comparison of an interactive voice response system and smartphone application in the identification of gout flares.

Elmagboul N, Coburn BW, Foster J, Mudano A, Melnick J, Bergman D, Yang S, Redden D, Chen L, Filby C, Curtis JR, Mikuls TR, Saag KG.

Arthritis Res Ther. 2019 Jun 29;21(1):160. doi: 10.1186/s13075-019-1944-5.

21.

Reply.

Saag KG, Geusens P, Lems WF.

Arthritis Rheumatol. 2019 Oct;71(10):1771-1772. doi: 10.1002/art.41013. Epub 2019 Sep 2. No abstract available.

PMID:
31215773
22.

Is there a role for cherries in the management of gout?

Collins MW, Saag KG, Singh JA.

Ther Adv Musculoskelet Dis. 2019 May 17;11:1759720X19847018. doi: 10.1177/1759720X19847018. eCollection 2019. Review.

23.

Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis.

Adami G, Saag KG.

Curr Rheumatol Rep. 2019 May 23;21(7):34. doi: 10.1007/s11926-019-0836-7. Review.

PMID:
31123839
24.

A Qualitative Study of the Postoperative Pain Management Educational Needs of Total Joint Replacement Patients.

Lemay CA, Saag KG, Franklin PD.

Pain Manag Nurs. 2019 Aug;20(4):345-351. doi: 10.1016/j.pmn.2018.12.009. Epub 2019 May 17.

PMID:
31109879
25.

Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.

Singh JA, Fraenkel L, Green C, Alarcón GS, Barton JL, Saag KG, Hanrahan LM, Raymond SC, Kimberly RP, Leong AL, Reyes E, Street RL Jr, Suarez-Almazor ME, Eakin GS, Marrow L, Morgan CJ, Caro B, Sloan JA, Jandali B, Garcia SR, Grossman J, Winthrop KL, Trupin L, Dall'Era M, Meara A, Rizvi T, Chatham WW, Yazdany J.

PLoS Med. 2019 May 8;16(5):e1002800. doi: 10.1371/journal.pmed.1002800. eCollection 2019 May.

26.

Glucocorticoid-induced osteoporosis update.

Adami G, Saag KG.

Curr Opin Rheumatol. 2019 Jul;31(4):388-393. doi: 10.1097/BOR.0000000000000608.

PMID:
31045947
27.

Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region.

Wu CH, Chang YF, Chen CH, Lewiecki EM, Wüster C, Reid I, Tsai KS, Matsumoto T, Mercado-Asis LB, Chan DC, Hwang JS, Cheung CL, Saag K, Lee JK, Tu ST, Xia W, Yu W, Chung YS, Ebeling P, Mithal A, Ferrari SL, Cooper C, Lin GT, Yang RS.

J Clin Densitom. 2019 Mar 20. pii: S1094-6950(19)30036-8. doi: 10.1016/j.jocd.2019.03.004. [Epub ahead of print]

PMID:
31010789
28.

Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages.

Curtis JR, Foster PJ, Saag KG.

Rheum Dis Clin North Am. 2019 May;45(2):275-289. doi: 10.1016/j.rdc.2019.01.010. Review.

PMID:
30952398
29.

Changing rates in fracture trends are temporally associated with declining testing and treatment: reality or ecologic fallacy?

Wright NC, Blackston JW, Saag KG.

Curr Opin Rheumatol. 2019 May;31(3):316-320. doi: 10.1097/BOR.0000000000000596.

PMID:
30920974
30.

Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.

Fassio A, Adami G, Benini C, Vantaggiato E, Saag KG, Giollo A, Lippolis I, Viapiana O, Idolazzi L, Orsolini G, Rossini M, Gatti D.

Bone. 2019 Jun;123:191-195. doi: 10.1016/j.bone.2019.03.019. Epub 2019 Mar 22.

PMID:
30910600
31.

Patient-Centered Outcomes and Key Study Procedure Finalization in the Pilot Feasibility Gout Randomized Trial: Comparative Feasibility Study in GOUt, CHerry Extract Versus Diet Modification (Mini-GOUCH).

Singh JA, Willig AL, Darnell B, Green C, Morgan S, Weiss R, Saag KG, Cutter G, McGwin G.

J Clin Rheumatol. 2019 Mar 12. doi: 10.1097/RHU.0000000000001018. [Epub ahead of print]

PMID:
30870252
32.

Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.

Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.

Arthritis Rheumatol. 2019 Jul;71(7):1174-1184. doi: 10.1002/art.40874. Epub 2019 May 25.

33.

Glucocorticoid-induced osteoporosis: 2019 concise clinical review.

Adami G, Saag KG.

Osteoporos Int. 2019 Jun;30(6):1145-1156. doi: 10.1007/s00198-019-04906-x. Epub 2019 Feb 25. Review.

PMID:
30805679
34.

Cost-Effectiveness of Osteoporosis Screening Using Biomechanical Computed Tomography for Patients With a Previous Abdominal CT.

Pisu M, Kopperdahl DL, Lewis CE, Saag KG, Keaveny TM.

J Bone Miner Res. 2019 Jul;34(7):1229-1239. doi: 10.1002/jbmr.3700. Epub 2019 Mar 24.

PMID:
30779860
35.

Race Plays a Role in the Knowledge, Attitudes, and Beliefs of Women with Osteoporosis.

Wright NC, Melton ME, Sohail M, Herbey I, Davies S, Levitan EB, Saag KG, Ivankova NV.

J Racial Ethn Health Disparities. 2019 Aug;6(4):707-718. doi: 10.1007/s40615-019-00569-w. Epub 2019 Feb 11.

PMID:
30747331
36.

A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout.

Singh JA, Green C, Morgan S, Willig AL, Darnell B, Saag KG, Weiss R, Cutter G, McGwin G.

J Clin Rheumatol. 2019 Jan 23. doi: 10.1097/RHU.0000000000001004. [Epub ahead of print]

PMID:
30702450
37.

Sex differences in osteoporosis self-efficacy among community-residing older adults presenting for DXA.

Solimeo SL, Nguyen VT, Edmonds SW, Lou Y, Roblin DW, Saag KG, Cram P, Wolinsky FD.

Osteoporos Int. 2019 May;30(5):1033-1041. doi: 10.1007/s00198-019-04854-6. Epub 2019 Jan 30.

PMID:
30701343
38.

Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.

Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, Redden DT, Saag KG, Foster PJ, Chen L, Curtis JR.

Am J Med. 2019 Mar;132(3):354-361. doi: 10.1016/j.amjmed.2018.11.011. Epub 2018 Nov 29.

PMID:
30503879
39.

Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.

Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, Al-Daghri N, Bruyère O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S.

Osteoporos Int. 2019 Jan;30(1):45-57. doi: 10.1007/s00198-018-4744-x. Epub 2018 Oct 31.

40.

Importance of Recent Fracture as Predictor of Imminent Fracture Risk.

Schnell AD, Curtis JR, Saag KG.

Curr Osteoporos Rep. 2018 Dec;16(6):738-745. doi: 10.1007/s11914-018-0487-z. Review.

PMID:
30368717
41.

Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.

Silverman S, Langdahl BL, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH.

Calcif Tissue Int. 2019 Feb;104(2):193-200. doi: 10.1007/s00223-018-0485-2. Epub 2018 Oct 20.

PMID:
30343436
42.

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE.

Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23781. [Epub ahead of print]

43.

The prevalence of overtreatment of osteoporosis: results from the PAADRN trial.

Hall SF, Wright NC, Wolinsky FD, Lou Y, Edmonds S, Roblin D, Jones M, Saag K, Cram P.

Arch Osteoporos. 2018 Sep 28;13(1):103. doi: 10.1007/s11657-018-0517-6.

PMID:
30267162
44.

Correction to: Hip fracture trends in the United States, 2002 to 2015.

Lewiecki EM, Wright NC, Curtis JR, Siris E, Gagel RF, Saag KG, Singer AJ, Steven PM, Adler RA.

Osteoporos Int. 2018 Nov;29(11):2583. doi: 10.1007/s00198-018-4685-4.

PMID:
30151621
45.

Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials.

Bamman MM, Cutter GR, Brienza DM, Chae J, Corcos DM, DeLuca S, Field-Fote E, Fouad MN, Lang CE, Lindblad A, Motl RW, Perna CG, Reisman D, Saag KM, Savitz SI, Schmitz KH, Stevens-Lapsley J, Whyte J, Winstein CJ, Michel ME.

Arch Phys Med Rehabil. 2018 Dec;99(12):2637-2648. doi: 10.1016/j.apmr.2018.08.173. Epub 2018 Aug 24.

PMID:
30148997
46.

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.

Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB.

Rheumatology (Oxford). 2019 Jan 1;58(1):61-69. doi: 10.1093/rheumatology/key245.

47.

Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain.

Singh JA, Curtis JR, Saag KG.

JAMA. 2018 Aug 7;320(5):508. doi: 10.1001/jama.2018.6937. No abstract available. Erratum in: JAMA. 2018 Sep 25;320(12):1288.

PMID:
30088001
48.

Moving Career Development Upstream: Evaluation of a Course for Internal Medicine Trainees Contemplating Career Pathways in Academic Medicine.

Kraemer RR, Wakelee JF, Hites L, Frank SJ, Saag K, Rogers DA, Nellore A, Erdmann N, Nichols AC, Merlin JS.

South Med J. 2018 Aug;111(8):471-475. doi: 10.14423/SMJ.0000000000000844.

49.

Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.

Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, Gunawardhana L.

Arthritis Rheumatol. 2019 Jan;71(1):143-153. doi: 10.1002/art.40685.

50.

Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm.

Day AL, Morgan SL, Saag KG.

Ther Adv Musculoskelet Dis. 2018 Jul;10(7):151-156. doi: 10.1177/1759720X18779761. Epub 2018 Jun 15.

Supplemental Content

Support Center